Breaking News
Get 45% Off 0
🤖 Are you in? These 5 AI-picked stocks are up 15%+
Read article

Stock Markets Analysis & Opinion

Contribute
Zacks Investment Research
Glaxo (GSK) Earnings And Revenues Surpass Estimates In Q4 By Zacks Investment Research - Feb 07, 2018

GlaxoSmithKline plc (NYSE:GSK) reported core earnings of 72 cents per American depositary share in the fourth quarter of 2017, surpassing the Zacks Consensus Estimate of 69 cents. The bottom line...

Zacks Investment Research
Goodyear (GT) Q4 Earnings & Revenues Beat Estimates, Up Y/Y By Zacks Investment Research - Feb 07, 2018

The Goodyear Tire & Rubber Company (NASDAQ:GT) reported adjusted earnings per share of 99 cents in comparison to 95 cents in the prior-year quarter. Moreover, the bottom line surpassed the Zack...

Zacks Investment Research
Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow By Zacks Investment Research - Feb 07, 2018

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported fourth-quarter of 2017 results wherein both earnings and sales beat expectations on the back of strong performance of eye-care drug Eylea.The...

Zacks Investment Research
Willis Towers (WLTW) Q4 Earnings And Revenues Beat Estimates By Zacks Investment Research - Feb 07, 2018

Willis Towers Watson Public Limited Company (NASDAQ:WLTW) reported fourth-quarter 2017 adjusted earnings of $2.21 per share, surpassing the Zacks Consensus Estimate of $2.11 by 4.7%. Also, the...

Zacks Investment Research
Markel's (MKL) Q4 Earnings Miss, Revenues Beat Estimates By Zacks Investment Research - Feb 07, 2018

Markel Corporation (NYSE:MKL) reported fourth-quarter 2017 income of $6.64 per share, missing the Zacks Consensus Estimate of $8.55. The bottom line also declined 27.1% year over year.Markel...

Zacks Investment Research
Cardinal Health (CAH) Beats On Q2 Earnings, Raises '18 View By Zacks Investment Research - Feb 07, 2018

Cardinal Health Inc. (NYSE:CAH) reported second-quarter fiscal 2018 adjusted earnings of $1.51 per share, which beat the Zacks Consensus Estimate of $1.14.However, excluding 20 cents benefit from...

Zacks Investment Research
Torchmark (TMK) Q4 Earnings Beat Estimates, Revenues In Line By Zacks Investment Research - Feb 07, 2018

Torchmark Corporation’s (NYSE:TMK) fourth-quarter 2017 net operating income of $1.24 per share beat the Zacks Consensus Estimate by 0.8%. The bottom line improved nearly 7.8% year over year...

Zacks Investment Research
Quest Diagnostics Banks On Alliances, Long-Term View Solid By Zacks Investment Research - Feb 07, 2018

On Feb 6, we issued an updated research report on Quest Diagnostics, Inc. (NYSE:DGX) , a major commercial laboratory services provider. The stock carries a Zacks Rank #2 (Buy).Shares of Quest...

Zacks Investment Research
IMAX To Expand Latin American Base Through Supercines Deal By Zacks Investment Research - Feb 07, 2018

IMAX Corporation (NYSE:IMAX) has recently announced a sales agreement with Supercines, the largest movie chain in Ecuador. The deal is to install five new IMAX theatres across the South American...

Zacks Investment Research
NY Times (NYT) Tops On Q4 Earnings, Digital Subscribers Rise By Zacks Investment Research - Feb 07, 2018

The New York Times Company (NYSE:NYT) posted sixth straight quarter of positive earnings surprise, when it reported fourth-quarter 2017 results. The company delivered adjusted earnings from...

Zacks Investment Research
Kellogg (K) Q4 Earnings In Line, Revenues Beat Estimates By Zacks Investment Research - Feb 07, 2018

Kellogg Company’s (NYSE:K) fourth-quarter 2017 adjusted earnings came in line with the Zacks Consensus Estimate while revenues surpassed the same. Cost-saving initiatives as well as higher...

Zacks Investment Research
O'Reilly (ORLY) Q4 Earnings & Revenues Surpass Estimates By Zacks Investment Research - Feb 07, 2018

O’Reilly Automotive Inc. (NASDAQ:ORLY) reported adjusted earnings of $2.9 per share in fourth-quarter 2017, beating the Zacks Consensus Estimate of $2.78. The bottom line was $2.59 in the...

Zacks Investment Research
Biogen Halts Tysabri Development In Stroke As Study Fails By Zacks Investment Research - Feb 07, 2018

Biogen Inc. (NASDAQ:BIIB) announced that its multiple sclerosis (MS) product, Tysabri (natalizumab) failed to meet the primary and secondary endpoints in a phase IIb study, evaluating the medicine...

Zacks Investment Research
Viacom (VIAB) Q1 Earnings Surpass Estimates, Decrease Y/Y By Zacks Investment Research - Feb 07, 2018

Viacom (NASDAQ:VIAB) reported mixed results in the first quarter of fiscal 2018 (ended Dec 31, 2017), wherein earnings per share outpaced the Zacks Consensus Estimate but revenues lagged the...

Zacks Investment Research
Cincinnati Financial (CINF) Q4 Earnings Top, Revenues Up Y/Y By Zacks Investment Research - Feb 07, 2018

Cincinnati Financial Corporation (NASDAQ:CINF) reported fourth-quarter 2017 operating income of 93 cents per share, beating the Zacks Consensus Estimate of 86 cents by 8.1%. Also, the bottom line...

Continue with Apple
Continue with Google
or
Sign up with Email